Meanwhile, with the acceleration of decentralized trial sites throughout the COVID ... these hardships are enough to turn some physicians away from clinical research. Alexander Saint-Amand is ...

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer. Phase 2 Study Assessing Alisertib in Metastatic ...

Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment. Dubbed Muse, the tool aims to cut ...

Senior author David Kirsch, M.D., Ph.D., leader of the Stand Up To Cancer (SU2C) Catalyst Research Team, which ran the clinical trial, and head of the Radiation Medicine Program at Princess ...

Insilico Medicine announced results from a clinical trial of ISM001-055, which the company designed using generative AI in order to treat idiopathic pulmonary fibrosis, a chronic lung disease ...

The successful completion of this clinical trial on the body fat-reducing effects of kimchi indicates that a steady consumption of kimchi is effective in alleviating obesity symptoms through the ...

which may lead to improved clinical trial enrollment and faster progress in medical research. A team of researchers from NIH's National Library of Medicine (NLM) and National Cancer Institute ...

Medable is bringing generative AI into its clinical trial platform in hopes that the tech will reduce the burden of repetitive tasks on trial sponsors, the company announced in a Nov. 12 release.

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. After treatment you see your doctor regularly to make sure the cancer isn’t coming back. If ...

Results from a clinical trial ... Innovative Immunotherapy Shows Promise in Early Clinical Trial for Breast Cancer Dec. 5, 2024 — A groundbreaking phase one clinical trial explored a novel cell ...

Call me cranky or old-fashioned, but I believe companies developing genetic medicines for even the rarest and most severe diseases should be conducting randomized, placebo-controlled clinical trials.